Elimination of 1,3,7-trimethylxanthine in laboratory animals during the induction of fatty hepatosis

Liver pathologies play a significant role in changing the metabolism and clearance of a  number  of  pharmacologically  active  substances,  including  1,3,7-trimethylxanthine, which is explained by their influence on enzyme systems that regulate the biotransformation of exogenous biologically active substances. Currently, changes in caffeine clearance  are  being  actively  studied  in  various hepatobiliary disorders, especially those that are chronic, since it is precisely such pathologies, according to a number of researchers, that are characterized by the most predictable  and  stable  change  in  the  trimethylxanthine  pharmacokinetic  profile.  The  purpose of  the  study  was  to  determine  changes  in serum  caffeine  levels  when  inducing  fatty liver  disease  in  laboratory  animals  (rats). The studies were carried out in the vivarium of  the  Department  of  Pharmacology  and Toxicology  of  the  Federal  State  Budgetary Educational Institution of Higher Education of St. Petersburg State University of Medicine.  Laboratory  animals  from  a  previous series of experiments were selected for the study  in  order  to  further  compare  the “caffeine curves.” Fatty hepatosis was modeled using strontium sulfate according to the methodology  developed  at  the  Department of  Pharmacology  and  Toxicology.  Upon completion of induction, fatty hepatosis was confirmed based on clinical and biochemical signs.  Based  on  the  studies  conducted,  we can conclude that there are certain correlations.  For  example,  in  fatty  hepatosis,  the elimination  of  caffeine  is  not  significantly slowed down with a characteristic long plateau (up to 8 hours after administration), turning into a smooth decrease in concentration. Experimental  data  can  be  used  to  create  a database to assess the relationship between pharmacokinetics and the physiological state of animals. Similar experiments need to be carried out on other animal species, which will create a holistic picture and help in assessing  pathologies  for  veterinary  specialists.

1. Lebeau, P.F. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance / P. F. Lebeau, J. H. Byun, K. Platko [et al.] // Nature Communications. – 2022. – Vol. 13, No. 1. – DOI 10.1038/s41467-022-28240-9.

2. Duthaler, U. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently / U. Duthaler, F. Bachmann, C. Suenderhauf [et al.] // Clinical Pharmacokinetics. – 2022. – Vol. 61, No. 7. – P. 1039-1055. – DOI 10.1007/s40262-022-01119-0.

3. Abduljalil, Kh. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population / Kh. Abduljalil, X. Pan, A. Pansari [et al.] // Clinical Pharmacokinetics. – 2020. – Vol. 59, No. 4. – P. 501-518. – DOI 10.1007/s40262-019-00827-4.

4. Nehlig, A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption / A. Nehlig // Pharmacological Reviews. – 2018. – Vol. 70, No. 2. – P. 384-411. – DOI 10.1124/pr.117.014407.

5. Gajewska, M. In vitro-to-in vivo correlation of the skin penetration, liver clearance and hepatotoxicity of caffeine / M. Gajewska, A. Paini, J. V. Sala Benito [et al.] // Food and Chemical Toxicology. – 2015. – Vol. 75. – P. 39-49. – DOI 10.1016/j.fct.2014.10.017.

6. Martín, A. Caffeine: Forms of consumption, toxicity, therapeutic effects and their use in medicine / A. Martín, M. Iturbe, A. Quintano [et al.] // Caffeine: Consumption, Side Effects and Impact on Performance and Mood, 2014. – P. 35-88.

7. Tangkuvanich, P. Caffeine clearance study in hepatocellular carcinoma / P. Tangkuvanich, S. Wittayalertpanya, T. Kusonsolboon [et al.] // Journal of the Medical Association of Thailand. – 1999. – Vol. 82, No. 3. – P. 297-303.

8. Falcão, A.C. Population pharmacokinetics of caffeine in premature neonates / A. C. Falcão, M. M. F. De Gatta, M. F. D. Iribarnegaray [et al.] // European Journal of Clinical Pharmacology. – 1997. – Vol. 52, No. 3. – P. 211-217. – DOI 10.1007/s002280050276.

9. Popova, O.S. Pharmacokinetic parameters of caffeine in laboratory animals in the context of assessing the functional state of the liver / O. S. Popova, V. S. Ponamarev, A. V. Kostrova, L. A. Agafonova // International Veterinary Bulletin. – 2023. – No. 2. – P. 142-149. – DOI 10.52419/issn2072-2419.2023.2.142.

10. Patent No. 2766772 C1 Russian Federation, IPC G09B 23/28, A61P 1/16. Method for modeling fatty liver using strontium sulfate: No. 2021113112: application. 05.05.2021: publ. 03.15.2022 / V. S. Ponamarev, A. M. Lunegov, V. A. Baryshev, K. F. Zenkov; applicant Federal State Budgetary Educational Institution of Higher Education St. Petersburg State University of Veterinary Medicine.

11. European Convention for the Protection of Vertebrate Animals Used for Experimental or Other Scientific Purposes (Strasbourg, 18 March 1986). Available from: https://rm.coe.int/168007a6a8. Link active as of October 27, 2023

12. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Available from: https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF. Link active as of October 27, 2023

13. Biochemistry of the liver and laboratory assessment of its physiological and biochemical state: educational manual / O. S. Belonovskaya, A. A. Lisitsyna, L. Yu. Karpenko, A. A. Bakhta. – St. Petersburg: St. Petersburg State Academy of Veterinary Medicine, 2014. – 116 p.

14. The concept and significance of Student’s criterion in clinical medicine / M. A. Polidanov, I. S. Blokhin, A. A. Skorokhod [etc.] // Modern Science. – 2020. – No. 2-1. – pp. 227-230.